POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Russia gives permission to launch clinical trials of nasal spray COVID-19 vaccine

Christian Fernsby |
A clinical trials program for a nasal spray coronavirus vaccine has been prepared and permission has been given to launch phase one clinical trials on adult volunteers, Russian Prime Minister Mikhail Mishustin announced at President Vladimir Putin’s meeting with cabinet members on Wednesday.

Article continues below

"Preclinical trials have already been conducted, they showed that the vaccine is safe and effective, a clinical trials program has been prepared," Mishutin said. According to him, "permission has been given to launch phase one clinical trials on adult volunteers." "It needs to be done in order to once again assess the safety and effectiveness of the vaccine and determine the right dosage," the prime minister specified.

Mishustin noted that "an interim report will be presented 42 days after the launch, which is required for the medication’s registration, and simultaneously, phase three trials will begin."

Mishustin noted that the head of state had earlier ordered him to take up the issue of clinical trials of the GamCovidVac nasal spray coronavirus vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. The prime minister emphasized that "all the necessary funds have been earmarked."

What to read next

Finnish researchers secure funding to develop nasal spray COVID-19 vaccine
Gamaleya Center ready to launch clinical trials of nasal spray coronavirus vaccine
FDA approves first generic naloxone nasal spray to treat opioid overdose